HNSCC	head and neck squamous cell carcinoma
LA-HNSCC	locally advanced head and neck squamous cell carcinoma
R/M-HNSCC	recurrent /metastatic head and neck squamous cell carcinoma
ICI	immune checkpoint inhibitor
CPS	combined positive score
CDDP	cisplatin
CBDCA	carboplatin
5-FU	5-fluorouracil
DTX	docetaxel
PTX	paclitaxel
FP	CDDP + 5-FU
FC	CBDCA + 5-FU
PCE	paclitaxel + carboplatin + cetuximab
Pem	pembrolizumab
PD-1	programmed cell death-1
PD-L1	programmed cell death 1-ligand 1
CRT	chemo-radiotherapy
BRT	bio- radiotherapy
EGFR	epidermal growth factor receptor
TGF-α	transforming growth factor-α
HER2	human epidermal growth factor receptor-type 2
MET	mesenchymal-epithelial transition factor
CTLA-4	cytotoxic T-lymphocyte antigen-4
NCCN	National Comprehensive Cancer Network
OS	overall survival
CR	complete response
PR	partial response
SD	stable disease
BSC	best supportive care
HPV	human papilloma virus
EBV	epstein-Barr virus
QOL	quality of life
NLR	neutrophil-to-lymphocyte ratio
irAE	immune-related adverse event
NGS	next generation sequencing
scRNA-seq	single-cell RNA-sequence
p-EMT	partial epithelial-to-mesenchymal transition
NIR-PIT	near infrared photoimmunotherapy
NCI	National Cancer Institute
NIH	National Institutes of Health
IR700	IRDye700DX
ICD	immunogenic cell death
DC	dendritic cell
ASCO	American society of clinical oncology
HDAC	histone deacetylase